January of 2016, Michelle Wilson was diagnosed with Carcinoid/Neuroendocrine Tumor (NET)--a rare form of liver cancer with only 25k cases worldwide. She has been receiving medication that no longer suppresses the cancer growth, so she’s turned to other options. Her family seeks treatment available in Europe called Peptide Receptor Radionuclide Therapy (PRRT), but one that has not been approved by the FDA here in the US. This treatment has been available for over a decade, and holds promising results-but due to its limited reach and location, costs are unreachable for this family. Michelle’s children attend Discovery Middle School.